{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:12:31Z","timestamp":1767852751880,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T00:00:00Z","timestamp":1406073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s10067-014-2748-2","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T03:22:06Z","timestamp":1405999326000},"page":"273-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["General adverse response to cyclophosphamide in Chinese patients with systemic autoimmune diseases in recent decade \u2014 a single-center retrospective study"],"prefix":"10.1007","volume":"34","author":[{"given":"Juan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guowei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,23]]},"reference":[{"key":"2748_CR1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ejim.2013.02.008","volume":"24","author":"T Brummaier","year":"2013","unstructured":"Brummaier T, Pohanka E, Studnicka-Benke A et al (2013) Using cyclophosphamide in inflammatory rheumatic diseases. Eur J Intern Med 24:590\u2013596","journal-title":"Eur J Intern Med"},{"key":"2748_CR2","first-page":"1150","volume":"33","author":"NE Sladek","year":"1973","unstructured":"Sladek NE (1973) Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo. Cancer Res 33:1150\u20131158","journal-title":"Cancer Res"},{"key":"2748_CR3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/bms.1200020109","volume":"2","author":"RF Struck","year":"1975","unstructured":"Struck RF, Kirk MC, Witt MH et al (1975) Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Biomed Mass Spectrom 2:46\u201352","journal-title":"Biomed Mass Spectrom"},{"key":"2748_CR4","first-page":"327","volume":"60","author":"RA Alarcon","year":"1976","unstructured":"Alarcon RA (1976) Studies on the in vivo formation of acrolein: 3-hydroxy-propylmercapturic acid as an index of cyclophosphamide (NSC-26271) activation. Cancer Treat Rep 60:327\u2013335","journal-title":"Cancer Treat Rep"},{"key":"2748_CR5","doi-asserted-by":"crossref","first-page":"11691","DOI":"10.1016\/S0021-9258(19)68462-0","volume":"256","author":"HL Gurtoo","year":"1981","unstructured":"Gurtoo HL, Marinello AJ, Struck RF et al (1981) Studies on the mechanism of denaturation of cytochrome P-450 by cyclophosphamide and its metabolites. J Biol Chem 256:11691\u201311701","journal-title":"J Biol Chem"},{"key":"2748_CR6","first-page":"44","volume":"16","author":"LG Koss","year":"1967","unstructured":"Koss LG (1967) A light and electron microscopic study of the effects of a single dose of cyclophosphamide on various organs in the rat: I. The urinary bladder. Lab Investig 16:44\u201365","journal-title":"Lab Investig"},{"key":"2748_CR7","first-page":"659","volume":"29","author":"N Brock","year":"1979","unstructured":"Brock N, Stekar J, Pohl J et al (1979) Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneimittelforschung 29:659\u2013661","journal-title":"Arzneimittelforschung"},{"key":"2748_CR8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejps.2005.08.008","volume":"27","author":"H Xie","year":"2006","unstructured":"Xie H, Griskevicius L, Stahle L et al (2006) Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci 27:54\u201361","journal-title":"Eur J Pharm Sci"},{"key":"2748_CR9","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/1097-0142(197511)36:5<1572::AID-CNCR2820360506>3.0.CO;2-T","volume":"36","author":"HJ Lawrence","year":"1975","unstructured":"Lawrence HJ, Simone J, Aur RJ (1975) Cyclophosphamide-induced hemorrhagic cystitis in children with leukemia. Cancer 36:1572\u20131576","journal-title":"Cancer"},{"key":"2748_CR10","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/rheumatology\/41.7.780","volume":"41","author":"GE Katsifis","year":"2002","unstructured":"Katsifis GE, Tzioufas AG, Vlachoyiannopoulos PG et al (2002) Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus. Rheumatology (Oxford) 41:780\u2013786","journal-title":"Rheumatology (Oxford)"},{"key":"2748_CR11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0022-5347(17)60025-9","volume":"111","author":"AH Bennett","year":"1974","unstructured":"Bennett AH (1974) Cyclophosphamide and hemorrhagic cystitis. J Urol 111:603\u2013606","journal-title":"J Urol"},{"key":"2748_CR12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11096-013-9756-1","volume":"35","author":"M Youssef","year":"2013","unstructured":"Youssef M, Mokni S, Belhadjali H et al (2013) Cyclophosphamide-induced generalised reticulated skin pigmentation: a rare presentation. Int J Clin Pharm 35:309\u2013312","journal-title":"Int J Clin Pharm"},{"key":"2748_CR13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1365-2133.1978.tb03587.x","volume":"98","author":"PC Shah","year":"1978","unstructured":"Shah PC, Rao KR, Patel AR (1978) Cyclophosphamide induced nail pigmentation. Br J Dermatol 98:675\u2013680","journal-title":"Br J Dermatol"},{"key":"2748_CR14","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/annonc\/mdt008","volume":"24","author":"C Vulsteke","year":"2013","unstructured":"Vulsteke C, Lambrechts D, Dieudonne A et al (2013) Genetic variability in the multidrug resistance associated protein-1 (ABCC1\/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol 24:1513\u20131525","journal-title":"Ann Oncol"},{"key":"2748_CR15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2125.2006.02690.x","volume":"62","author":"S Zhong","year":"2006","unstructured":"Zhong S, Huang M, Yang X et al (2006) Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br J Clin Pharmacol 62:457\u2013472","journal-title":"Br J Clin Pharmacol"},{"key":"2748_CR16","first-page":"759","volume":"97","author":"ME Beard","year":"1984","unstructured":"Beard ME, Conder JL, Clark VA (1984) Ovarian failure following cytotoxic therapy. N Z Med J 97:759\u2013762","journal-title":"N Z Med J"},{"key":"2748_CR17","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/art.21263","volume":"52","author":"EC Somers","year":"2005","unstructured":"Somers EC, Marder W, Christman GM et al (2005) Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 52:2761\u20132767","journal-title":"Arthritis Rheum"},{"key":"2748_CR18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1191\/0961203302lu163oa","volume":"11","author":"SG Pasoto","year":"2002","unstructured":"Pasoto SG, Mendonca BB, Bonfa E (2002) Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus 11:175\u2013180","journal-title":"Lupus"},{"key":"2748_CR19","first-page":"436","volume":"26","author":"SS Shabanova","year":"2008","unstructured":"Shabanova SS, Ananieva LP, Alekberova ZS et al (2008) Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol 26:436\u2013441","journal-title":"Clin Exp Rheumatol"},{"key":"2748_CR20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.autrev.2005.10.001","volume":"5","author":"K Manger","year":"2006","unstructured":"Manger K, Wildt L, Kalden JR et al (2006) Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev 5:269\u2013272","journal-title":"Autoimmun Rev"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2748-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-014-2748-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2748-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T21:33:10Z","timestamp":1649712790000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-014-2748-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,23]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["2748"],"URL":"https:\/\/doi.org\/10.1007\/s10067-014-2748-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,23]]}}}